Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nastech Pharmaceutical has completed enrollment for its Phase II clinical trial of PYY3-36 Nasal Spray to treat obesity.
Subscribe to our email newsletter
The company enrolled 551 obese patients at multiple clinical sites in the US for a six-month, randomized, placebo-controlled dose ranging study. The study is designed to evaluate three different doses of PYY3-36 Nasal Spray compared to placebo and sibutramine (Meridia), a commercially available oral weight loss drug, with the primary endpoint being weight loss.
Gordon Brandt, president of Nastech, said: “If successful, PYY Nasal Spray would offer a patient-friendly product to promote weight loss.”